Statement: 59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.
Primary_evidence: Outcome Measurement:    Clinical Benefit Response (Independent Reviewer-assessed)   CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks). A "complete response" is defined as the disappearance of all target or non-target lesions, "partial response" and "disease progression" as at least a 30% decrease and at least a 20% increase, respectively, in the sum of the longest diameter of target lesions, and "stable disease" as neither "partial response" nor "disease progression."   Time frame: Baseline, every 6 weeks until Week 24 and then every 12 weeks until disease progression (up to Week 119) Results 1:    Arm/Group Title: Lapatinib 1250 mg and Capecitabine 2000 mg/m^2   Arm/Group Description: Participants took lapatinib and capecitabine. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle.   Overall Number of Participants Analyzed: 51   Measure Type: Number   Unit of Measure: percentage of participants  59